Hard to Treat Diseases (HTDS)

[ORCA]

If what is read in the site comes to fruition, then King
deserves Gold Medal.I like the read below.Will love it if comes to fruition.Holding for 3 years now.Weeeeeeeeeeeee.
I love what I read on Bold:
http://www.htdsotc.com/

CORPORATE OVERVIEW
As an emerging biotech company, Hard To Treat Diseases, Inc. (“HTTD”) has developed its patent rights with aggressive testing that has been conducted in U.S. FDA approved laboratories. HTTD has positioned its biotech assets, including testing results, for acquisition by a major pharmaceutical firm.



The corporate headquarters for HTTD is in Delray Beach , Florida and all testing is conducted at institutions located in the U.S. that are FDA approved.



HTTD’s business model reflects having its biotech assets acquired by a major drug company. This transaction will achieve the goal of benefiting HTTD’s shareholders and the drug company will be responsible for achieving the goal of benefiting patients. The majority of successful drugs on the market are acquired by major drug firms from biotech companies. The major drug company that acquires HTTD’s assets will have the resources to gain FDA approval and decide if FDA “fast track” approval is possible. In addition, the acquiring company will obviously have the infrastructure to manufacture, market and distribute HTTD’s products globally and the resources to assure rapid development.



In December 2004, HTTD filed a provisional patent application for Methods and Compositions for Treatment of Viral Infections. This application provides a novel method for inhibition of viral infections and to the therapeutic treatment of diseases or disorders caused by such viral infections. The application became a utility patent application in December 2005. It will be available by the USPTO in full for review in June 2006 and scheduled for examination.



In December 2005, HTTD filed a provisional patent application for Methods and Compositions for Treatment of Cancer. This application provides a novel method for inhibition and prevention of cancer, to the diseases associated with such cancers and to the therapeutic treatment of diseases or disorders caused by such cancers. This application will became a utility patent application in December 2006.



HTTD’s patent applications are the result of testing conducted on two substances that were acquired by the Company for testing; Tubercin (T-5) and Specific Substance of Maruyama (“SSM”).



The rights to the composition, Tubercin (T-5), are owned by Dr. Chung of South Korea , the inventor and patent holder. Dr. Chung has licensed the rights to Tubercin (T-5) for the use in medical care of cancer to another party. SSM was developed and advanced by Zeria Pharmaceutical Co., Ltd. (“Zeria”) of Japan . This drug was also called Z-100 for clinical trials and is currently trade named Ancer 20. Zeria is currently using Ancer 20 injection for radiotherapy-induced leukopenia.



Tubercin (T-5), SSM or a functional derivative thereof can be used individually for treatment, as stated in the abstracts of HTTD’s patent applications. SSM is the substance that the Company will be presenting to pharmaceutical companies for acquisition regarding HTTD’s applications. Regardless of whether HTTD acquires marketing rights to Tubercin (T-5), HTTD solely owns and controls utility patent rights to the drug.



The Company has aggressively moved forward and advanced its position with the rights owned that were unencumbered, as opposed to waiting to secure rights that may be unnecessary.



The above patent applications are currently being packaged for presentation to major drug companies. Pharmaceutical companies that specialize in oncology and infectious diseases are the targeted candidates for the acquisition of these patent rights, testing and research. Protocols for additional testing that potentially may lead to new patent applications for the treatment of other diseases are included in the presentation to drug companies.



The Company's Board of Directors voted to spin-off its wholly-owned subsidiary, Cavit Sciences, Inc. ("Cavit"), to HTTD shareholders of record on June 13, 2006. HTTD had previously assigned certain of its patent application rights and related assets to Cavit, a corporation formed as a wholly-owned subsidiary of HTTD. Cavit shares were issued to HTTD as consideration for the assets acquired by Cavit. HTTD will distribute the Cavit shares as a stock dividend to the HTTD shareholders of record as of June 13, 2006. HTTD expects to pay the stock dividend on or about September 30, 2006.



HTTD is currently involved in litigation regarding the rights to Tubercin®. Additional information and details regarding the litigation can be viewed on this websites homepage by clicking on the top captions and by reviewing the press releases listed in the News section and by clicking on Corporate, then Legal and reviewing legal filings.



Recent court decisions and Company documentation have revealed that prior officers and directors of HTTD committed fraudulent acts, misled shareholders and investors, breached corporate duties, issued shares fraudulently and diverted recycling patents for personal gain. The Company is patiently waiting for the judiciary system and the Securities and Exchange Commission to protect the rights of HTTD’s shareholders